Anti-vascular endothelial growth factor for neovascular glaucoma
Arathi Simha, Kanza Aziz, Andrew Braganza, Lekha Abraham, Prasanna Samuel, Kristina Lindsley
Abstract
Neovascular glaucoma (NVG) is a potentially blinding, secondary glaucoma. It is caused by the formation of abnormal new blood vessels, which prevent normal drainage of aqueous from the anterior segment of the eye. Anti-vascular endothelial growth factor (anti-VEGF) medications are specific inhibitors of the primary mediators of neovascularization. Studies have reported the effectiveness of anti-VEGF medications for the control of intraocular pressure (IOP) in NVG.
Topics & Concepts
MedicineBlindingBevacizumabIntraocular pressureRandomized controlled trialClinical trialOphthalmologyLatanoprostMEDLINEMeta-analysisGlaucomaOptometryInternal medicineChemotherapyPolitical scienceLawRetinal Diseases and TreatmentsGlaucoma and retinal disordersRetinal Imaging and Analysis